|
|
Volumn 42, Issue 8, 2006, Pages 1187-1188
|
|
Oropharyngeal candidiasis: A new treatment option
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMPHOTERICIN B;
ANTIFUNGAL PEPTIDE;
ANTIRETROVIRUS AGENT;
CASPOFUNGIN;
CEFTRIAXONE;
CLOTRIMAZOLE;
CRYSTAL VIOLET;
CYCLOSPORIN;
CYTOCHROME P450;
ECHINOCANDIN;
ENZYME ACTIVATOR;
FLUCONAZOLE;
FLUCYTOSINE;
ITRACONAZOLE;
KETOCONAZOLE;
METRONIDAZOLE;
NYSTATIN;
POLYPEPTIDE ANTIBIOTIC AGENT;
POSACONAZOLE;
PROBIOTIC AGENT;
PYRROLE DERIVATIVE;
TSUKUBAENOLIDE;
TUBERCULOSTATIC AGENT;
UNCLASSIFIED DRUG;
VORICONAZOLE;
ACQUIRED IMMUNE DEFICIENCY SYNDROME;
ANTIFUNGAL ACTIVITY;
ANTIINFLAMMATORY ACTIVITY;
ANTINEOPLASTIC ACTIVITY;
BONE MARROW TRANSPLANTATION;
CANDIDA ALBICANS;
CLINICAL TRIAL;
COST EFFECTIVENESS ANALYSIS;
DRUG BLOOD LEVEL;
DRUG COST;
DRUG EFFICACY;
DYSGEUSIA;
HIGH RISK PATIENT;
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
NOTE;
OROPHARYNX CANDIDIASIS;
PRIORITY JOURNAL;
RELAPSE;
SIDE EFFECT;
AIDS-RELATED OPPORTUNISTIC INFECTIONS;
ANTIFUNGAL AGENTS;
CANDIDA ALBICANS;
CANDIDIASIS;
CANDIDIASIS, ORAL;
CLINICAL TRIALS;
HUMANS;
PHARYNGEAL DISEASES;
TRIAZOLES;
|
|
EID: 33645790503
PISSN: 10584838
EISSN: None
Source Type: Journal
DOI: 10.1086/501465 Document Type: Note |
|
Times cited : (9)
|
|
References (3)
|
